220 related articles for article (PubMed ID: 15315862)
21. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
[TBL] [Abstract][Full Text] [Related]
22. Purification and analysis of polyhistidine-tagged human parvovirus B19 VP1 and VP2 expressed in insect cells.
Michel PO; Mäkelä AR; Korhonen E; Toivola J; Hedman L; Söderlund-Venermo M; Hedman K; Oker-Blom C
J Virol Methods; 2008 Sep; 152(1-2):1-5. PubMed ID: 18598721
[TBL] [Abstract][Full Text] [Related]
23. Antibody-mediated opsonization of red blood cells in parvovirus B19 infection.
Chehadeh W; Halim MA; Al-Nakib W
Virology; 2009 Jul; 390(1):56-63. PubMed ID: 19450862
[TBL] [Abstract][Full Text] [Related]
24. Impaired gamma interferon responses against parvovirus B19 by recently infected children.
Corcoran A; Doyle S; Waldron D; Nicholson A; Mahon BP
J Virol; 2000 Nov; 74(21):9903-10. PubMed ID: 11024117
[TBL] [Abstract][Full Text] [Related]
25. Detection of parvovirus B19 nucleic acids and expression of viral VP1/VP2 antigen in human colon carcinoma.
Li Y; Wang J; Zhu G; Zhang X; Zhai H; Zhang W; Wang W; Huang G
Am J Gastroenterol; 2007 Jul; 102(7):1489-98. PubMed ID: 17459020
[TBL] [Abstract][Full Text] [Related]
26. Most of the VP1 unique region of B19 parvovirus is on the capsid surface.
Kawase M; Momoeda M; Young NS; Kajigaya S
Virology; 1995 Aug; 211(2):359-66. PubMed ID: 7544049
[TBL] [Abstract][Full Text] [Related]
27. Identification of an immunodominant peptide in the parvovirus B19 VP1 unique region able to elicit a long-lasting immune response in humans.
Zuffi E; Manaresi E; Gallinella G; Gentilomi GA; Venturoli S; Zerbini M; Musiani M
Viral Immunol; 2001; 14(2):151-8. PubMed ID: 11398810
[TBL] [Abstract][Full Text] [Related]
28. Molecular and structural characterization of fluorescent human parvovirus B19 virus-like particles.
Gilbert L; Toivola J; White D; Ihalainen T; Smith W; Lindholm L; Vuento M; Oker-Blom C
Biochem Biophys Res Commun; 2005 Jun; 331(2):527-35. PubMed ID: 15850791
[TBL] [Abstract][Full Text] [Related]
29. Human parvovirus B19 infection during pregnancy--value of modern molecular and serological diagnostics.
Enders M; Schalasta G; Baisch C; Weidner A; Pukkila L; Kaikkonen L; Lankinen H; Hedman L; Söderlund-Venermo M; Hedman K
J Clin Virol; 2006 Apr; 35(4):400-6. PubMed ID: 16332455
[TBL] [Abstract][Full Text] [Related]
30. Differential IgM response to conformational and linear epitopes of parvovirus B19 VP1 and VP2 structural proteins.
Manaresi E; Zuffi E; Gallinella G; Gentilomi G; Zerbini M; Musiani M
J Med Virol; 2001 May; 64(1):67-73. PubMed ID: 11285571
[TBL] [Abstract][Full Text] [Related]
31. Subunit interaction in B19 parvovirus empty capsids.
Rosenfeld SJ; Young NS; Alling D; Ayub J; Saxinger C
Arch Virol; 1994; 136(1-2):9-18. PubMed ID: 7516147
[TBL] [Abstract][Full Text] [Related]
32. Establishment of functional B cell memory against parvovirus B19 capsid proteins may be associated with resolution of persistent infection.
Corcoran A; Crowley B; Dewhurst C; Pizer BL; Doyle S
J Med Virol; 2006 Jan; 78(1):125-8. PubMed ID: 16299723
[TBL] [Abstract][Full Text] [Related]
33. Detection of parvovirus B19 IgG: choice of antigens and serological tests.
Manaresi E; Gallinella G; Venturoli S; Zerbini M; Musiani M
J Clin Virol; 2004 Jan; 29(1):51-3. PubMed ID: 14675870
[TBL] [Abstract][Full Text] [Related]
34. Circulating cytokines and chemokines in acute symptomatic parvovirus B19 infection: negative association between levels of pro-inflammatory cytokines and development of B19-associated arthritis.
Kerr JR; Cunniffe VS; Kelleher P; Coats AJ; Mattey DL
J Med Virol; 2004 Sep; 74(1):147-55. PubMed ID: 15258981
[TBL] [Abstract][Full Text] [Related]
35. The association of VP1 unique region protein in acute parvovirus B19 infection and anti-phospholipid antibody production.
Tzang BS; Tsay GJ; Lee YJ; Li C; Sun YS; Hsu TC
Clin Chim Acta; 2007 Mar; 378(1-2):59-65. PubMed ID: 17169353
[TBL] [Abstract][Full Text] [Related]
36. Undenatured parvovirus B19 antigens are essential for the accurate detection of parvovirus B19 IgG.
Kerr S; O'Keeffe G; Kilty C; Doyle S
J Med Virol; 1999 Feb; 57(2):179-85. PubMed ID: 9892405
[TBL] [Abstract][Full Text] [Related]
37. Seroprevalence of IgG against conformational and linear capsid antigens of parvovirus B19 in Italian blood donors.
Manaresi E; Gallinella G; Morselli Labate AM; Zucchelli P; Zaccarelli D; Ambretti S; Delbarba S; Zerbini M; Musiani M
Epidemiol Infect; 2004 Oct; 132(5):857-62. PubMed ID: 15473148
[TBL] [Abstract][Full Text] [Related]
38. Human parvovirus B19 serology and avidity using a combination of recombinant antigens enables a differentiated picture of the current state of infection.
Pfrepper KI; Enders M; Motz M
J Vet Med B Infect Dis Vet Public Health; 2005; 52(7-8):362-5. PubMed ID: 16316402
[TBL] [Abstract][Full Text] [Related]
39. Chimeric parvovirus B19 capsids for the presentation of foreign epitopes.
Brown CS; Welling-Wester S; Feijlbrief M; Van Lent JW; Spaan WJ
Virology; 1994 Feb; 198(2):477-88. PubMed ID: 7507280
[TBL] [Abstract][Full Text] [Related]
40. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
